menu search

Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve ...

November 3, 2023, 2:46 pm

Pipeline moves: approval prospects rise for oesophageal cancer drug after trial completion

On a good note, we investigate the completion of a Phase IIb trial in congestive heart failure and chronic kid...

November 2, 2023, 8:29 pm

Miromatrix medical stock soars after it agrees to be bought by united therapeutics

Miromatrix Medical Inc.'s stock MIRO, -2.80% jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics ...

October 30, 2023, 6:23 am

Novartis says drug candidate is successful in rare kidney disease trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function i...

October 30, 2023, 3:42 am

Novo nordisk just consolidated its grip on yet another market. is it a buy?

Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could als...

October 29, 2023, 9:30 am

Opko health to present new clinical data on rayaldee (er calcifediol) at kidney week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calc...

October 25, 2023, 8:25 pm

Opko health to present new clinical data on rayaldee (er calcifediol) at kidney week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calci...

October 25, 2023, 4:25 pm

Mallinckrodt to present data on terlivaz® (terlipressin) for injection in adult patients with hepatorenal syndrome (hrs) at the american college of gastroenterology (acg) annual scientific meeting

– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ,1 patients'...

October 22, 2023, 3:05 pm

Bristol myers' (bmy) opdivo sc meets kidney cancer study goals

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage ...

October 20, 2023, 6:46 am

Ardelyx (ardx) up on fda nod to xphozah for hyperphosphatemia

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney d...

October 19, 2023, 12:02 pm

Bristol myers's injectable kindey cancer drug found non-inferior to iv form

Bristol Myers Squibb said on Thursday its injectable form of blockbuster cancer drug Opdivo was found to be non-inferior to the approved intravenous f...

October 19, 2023, 7:11 am

Calliditas therapeutics to present seven abstracts at the american society of nephrology (asn) kidney week 2023

STOCKHOLM , Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven ab...

October 19, 2023, 3:58 am

Why ardelyx stock popped today

Late yesterday, Ardelyx announced that the FDA has approved its first-in-class chronic kidney disease d...

October 18, 2023, 4:31 pm

Fda sends ardx stock soaring after approving ardelyx's kidney disease drug

Ardelyx (NASDAQ: ARDX ) stock is climbing today after the U.S. Food and Drug Administration (FDA) approved the firm's treatment for excessive phosphat...

October 18, 2023, 10:42 am

: ardelyx wins long battle for fda approval of kidney-disease treatment 

Drug previously rejected by regulators gets green light and is set to launch later this year Read Full Story The post : Ardelyx wins long battle for F...

October 17, 2023, 11:24 pm

Ardelyx wins long battle for fda approval of kidney-disease treatment

Ardelyx Inc. ARDX, -0.58% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic ...

October 17, 2023, 7:24 pm

Prokidney corp. (prok) loses -54.93% in 4 weeks, here's why a trend reversal may be around the corner

Prokidney Corp. (PROK) is technically in oversold territory now, so the heavy selling pressure might ha...

October 17, 2023, 11:19 am

Eu regulator backs merck's viral infection drug

European health regulator backed Merck & Co's drug to treat a type of infection in adult kidney transpl...

October 17, 2023, 7:06 am

Is chamath palihapitiya giving up on prokidney (prok) stock?

Shares of Prokidney (NASDAQ: PROK ) are in the green today, despite recent sales from special purpose a...

October 16, 2023, 2:50 pm


Search within

Pages Search Results: